Multiple myeloma: five-year experience at a University Hospital

Todaro, Juliana; Bigonha, Jandey; Borducchi, Davimar Miranda Maciel; Matos, Leandro Luongo; Trufelli, Damila Cristina; Sales, Suzane Martines Alves de; Shiroma, Marina Rampazzo Del Valhe; Giglio, Auro del

doi:10.1590/S1679-45082011AO2006

home Sumário navigate_before Anterior Atual Seguinte navigate_next

home Sumário

Original Article • Einstein (São Paulo) 9 (2) • Apr-Jun 2011 • https://doi.org/10.1590/S1679-45082011AO2006 linkcopy

Multiple myeloma: five-year experience at a University Hospital

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstracts

Objective: To present a descriptive analysis of patients diagnosed with multiple myeloma, correlating it with mortality.

Methods: A retrospective study that analyzed consecutive patients diagnosed with multiple myeloma under follow-up at the Faculdade de Medicina do ABC from 2006 to 2010.

Results: The median age was 58.5 years. Anemia was observed upon diagnosis in 87% of patients, hypercalcemia in 38%, and creatinine levels higher than 2 mg/dL in 19%. M protein was detected in 85.7%. The five-year survival rate was 74.6%. Multivariate analysis showed statistical significance for Durie-Salmon staging (p = 0.037). The International Staging System and immunoglobulin type did not correlate significantly with survival of the group.

Conclusion: This set of cases from a tertiary public healthcare service reflect the approach of multiple myeloma in a predominantly young population with advanced clinical staging, with results comparable to those of the literature.

Multiple myeloma/therapy; Neoplasm staging; Survival

Characteristics			n	%
Age (years)			63
	< 40			5
	40 – 49			14
	50 – 59			29
	60 – 69			25
	70 – 79			24
	> ou = 80			3
Sex			73
	Male			56
	Female			44
Laboratory parameters			n	%
	Hemoglobin (g/dL)		55
		< 8.5 g/dL		25
		> 10 g/dL		31
	Platelets (× 109/L)		54
		< 100		5
		> 100		95
	Leukocytes (× 109/L)		54
		< 4		17
		> 10		9
	Creatinine (g/dL)		53
		< 2		81
		> 2		19
	Hypercalcemia		58
		Present		32
		Absent		68
	Immunoglobulin (subtype)		54
		IgG		48.1
		IGA		24.1
		Light chain		22.2
		Non secreting		5.6
		Bone lesions	61
		O		6
		I		20
		II		13
		III		61
Staging
	DSS		61
	I			1.6
	II			19.7
	III			78.7
	ISS		45
	I			28.9
	II			22.2
	III			10

Chemotherapeutical regimens		n	%
First line
	VAD	9	14.5
	Dexamethasone	10	16.1
	Thalidomide and dexamethasone	22	35.5
	Melphalan and prednisone	18	29.0
	Others	3	4.8
Total		62	100
Second line
	VAD	3	8.9
	Cyclophosphamide and dexamethasone	3	8.9
	Dexamethasone	4	11.7
	Melphalan and prednisone	5	14.7
	Thalidomide and dexamethasone	9	26.4
	Thalidomide	10	29.4
Total		34	100

vertical_align_top show_chart

more_horiz close
- image
- translate
- link
- article
- vertical_align_top
- file_download
- show_chart
- image
- translate
- link
- article

location_on

Instituto Israelita de Ensino e Pesquisa Albert Einstein Avenida Albert Einstein, 627/701 , 05651-901 São Paulo - SP, Tel.: (55 11) 2151 0904 - São Paulo - SP - Brazil
E-mail: revista@einstein.br

rss_feed Acompanhe os números deste periódico no seu leitor de RSS

[TFN1] DSS - Durie-Salmon stage

[TFN2] ISS - International Staging System